Levrett Plc CEO Pascal Hughes Whitman Howard, New Insights, Potential Acquisition

Levrett Plc (LON:LVRT) CEO Pascal Hughes talks to DirectorsTalk about the appointment of new broker Whitman Howard, insights from the San Francisco biotech conference and potential acquisition.

 

Mr Hughes is a financier, investor and entrepreneur. He previously worked in Investment Banking in the City of London for close to 20 years most recently as a Managing Director in Fixed Income, Currencies and Commodities at UBS bank. Prior to that he was a Managing Director in Global Banking and Markets at HSBC. He left UBS to become an active private investor and advisor to start-up companies in a variety of different business areas from financial technologies to oil field services. During this period he has been involved in developing businesses and advising on acquisition and turn round strategy. Pascal has a B.A (Hons) in Accounting and Finance from Dublin City University, and an MSc. in Financial Economics from Queens University Belfast.

Levrett plc is a special purpose acquisition company formed to acquire realisable and/or developed commercial technologies focused in the Pharmaceutical and Biotechnology sector.The Company draws on its expertise in the Pharmaceutical and Biotechnology sector to assess different propositions and initiate discussions via market contacts and professional advisers. In selecting acquisition opportunities to review, the Board will focus on entities that are available at attractive valuations and hold opportunities to unlock embedded value. Following completion of an acquisition, the objective will be to operate the acquired business and implement an operating strategy with a view to generating value for its shareholders through operational and product development as well as possible complimentary acquisitions.

 

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Levrett Plc

    More articles like this

    Levrett Plc

    Levrett Plc Final Results and Annual Report

    Levrett PLC (LON:LVRT), a Company formed to acquire a target company with realisable or developed commercial technologies in the pharmaceutical and biotechnology sector, today announced its final results for the period ended 31 March 2017 and

    Levrett Plc

    Levrett Plc Biotech: Bull market or Bubble?

    Levrett Plc (LON:LVRT), a Company formed to acquire a target company with realisable or developed commercial technologies in the pharmaceutical and biotechnology sector, today made the following comment regarding the Timmerman Report which was published earlier

    Levrett Plc

    Levrett Plc Big data in biotech

    Alphabet Inc (NASDAC:GOOGL) executive chairman Eric Schmidt on Monday pointed out six game changing technologies, or what he calls moonshots, that he thinks will improve important parts of society. This was highlighted on the fortune.com website.

    Levrett Plc

    Levrett Plc comments on an unprecedented cancer research effort

    Levrett Plc (LON:LVRT) CEO Pascal Hughes, said: “Sean Parker of Napster and Facebook fame joins a list of tech based philanthropists starting initiatives in the Biotech and Lifescience sector with this collaborative initiative in immuno-oncology which

    Levrett Plc

    Levrett Plc Strategy, Biotechnology, Success and Focus

    Levrett Plc (LON:LVRT) Chief Executive Officer Pascal Hughes caught up with DirectorsTalk to chat about strategy, the biotech sector, the future for this sector and due diligence. Levrett Plc, a Company formed to acquire a target